Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

Yang, Zijian; Suda, Goki; Maehara, Osamu et al.

Cancers, 2023, 15(3), 593

Permalink : https://hdl.handle.net/2115/89182

このアイテムのアクセス数:283件（2026-08-18 01:55 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.3390/cancers15030593     94

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/89182
タイトル
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
著者
Yang, Zijian ; Suda, Goki ; Maehara, Osamu ; Ohara, Masatsugu ; Yoda, Tomoka ; Sasaki, Takashi ; Kohya, Risako ; Yoshida, Sonoe ; Hosoda, Shunichi ; Tokuchi, Yoshimasa ; Kitagataya, Takashi ; Suzuki, Kazuharu ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Ogawa, Koji ; Ohnishi, Shunsuke ; Sakamoto, Naoya
著者名
Yang, Zijian
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Maehara, Osamu
著者名
Ohara, Masatsugu
著者名
Yoda, Tomoka
著者名
Sasaki, Takashi
著者名
Kohya, Risako
著者名
Yoshida, Sonoe
著者名
Hosoda, Shunichi
著者名
Tokuchi, Yoshimasa
著者名
Kitagataya, Takashi
著者名
Suzuki, Kazuharu
著者名
Kawagishi, Naoki
著者名
Nakai, Masato
著者名
Sho, Takuya
著者名
Natsuizaka, Mitsuteru
著者名
Ogawa, Koji
著者名
Ohnishi, Shunsuke
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
キーワード
resistance
mechanism
immune checkpoint inhibitor
atezolizumab
bevacizumab
hepatocellular carcinoma
progressive disease
VEGF-D
angiopoietin-2
発行日
2023-02
出版者
MDPI
収録物名
Cancers
巻(号)
15(3)
ページ
593
抄録
Simple Summary The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC and the subsequent response to these therapies remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Growth factor changes between the baseline and best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3390/cancers15030593